Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07564141 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
A Phase 3 study, sponsored by Genmab.
- Not yet
- Registry status
- Phase 3
- Development phase
- 688
- Enrollment target
NCT07564141 is a Phase 3 study that has not yet begun recruiting, run by Genmab. The registered enrollment target is 688 participants.
The verdict
NCT07564141, a Phase 3 study, has not yet begun recruiting, sponsored by Genmab.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 688 participants
- Enrollment target
Study Summary
This Phase 3 study will be conducted in different countries around the world with up to about 688 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with or without bevacizumab and how it compares to an investigator's choice of platinum-based chemotherapy with or without bevacizumab. Participants will receive either: * Rina-S monotherapy (by itself), * Rina-S plus bevacizumab, * investigator's choice chemotherapy (by itself) (standard of care), or * investigator's choice chemotherapy plus bevacizumab (standard of care). No participants will be given placebo. Participants will participate in 1 of 2 arms. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 or 4 weeks, depending on medication received). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) will be different for every participant.
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Gemcitabine
- BIOLOGICAL Rina-S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 688 participants |
| Start Date | 2026-07 |
| Est. Completion | 2031-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07564141
The ClinicalTrials.gov registry entry for NCT07564141 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 688 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT07564141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07564141 about?
NCT07564141 is a clinical study titled "Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer". This Phase 3 study will be conducted in different countries around the world with up to about 688 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with or without bevacizumab and how it compares to an investigator's choice of platinu...
What is the current status of trial NCT07564141?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 688 participants. The study started on 2026-07. Estimated completion is 2031-11.
What interventions are being tested in trial NCT07564141?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG), Gemcitabine (DRUG), Rina-S (BIOLOGICAL).
Who is sponsoring clinical trial NCT07564141?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.